CS Paper Radar

An immune world model for multiscale forecasting and therapeutic hypothesis generation

Taoyong Cui, Xi Wang, Zonghang Li, Jinchao Ding, Lingsen You, Yuzhi Xu, Wanghan Xu, Fang Wu, Kejun Ying, Wanli Ouyang, Pheng Ann Heng, Ling Yang, Zhenfei Yin, Yingcheng Wu

cs.LG q-bio.QM ·submitted 2026-09-13 18:06 UTC · v1
highly cited

Abstract

Immune therapies act across cell-intrinsic programs, tissue ecosystems, and patient-specific immune states, yet most predictors address these scales separately. We used a governed evolutionary AI Scientist to construct the Immune World Model, an action-conditioned model that learns how interventions move immune states across cellular, tissue, and individual levels. The Immune World Model--building Scientist searched candidate architectures and workflows, and the resulting world model was frozen before independent confirmation. The frozen model generalized to unseen interventions and biological contexts, recovered intervention-specific cellular programs, integrated cell and tissue information to improve ecosystem and patient-response prediction, and forecast unseen perturbation combinations. Immune World Model--guided analysis then combined measured perturbations with cross-axis inference to nominate IL-36$γ$ plus SIRP$α$ inhibition as a complementary-axis therapeutic hypothesis, whereas a governed self-correction audit rejected every screened cytokine pair. The Immune World Model provides a framework for multiscale immune simulation that connects AI Scientist-driven model construction, intervention forecasting, and the generation of prospectively testable therapeutic hypotheses.

Closest papers

Nearest neighbours by meaning across the whole index.

Multimodal reasoning for broadly neutralizing antibody discovery from label-free human B cell repertoires across virus families

cs.AI q-bio.QMcs.CEq-bio.CB ·2026-10-02 ·Hantao Lou, Jianqing Zheng, Can Yue, Meihan Zhang, Yuanchao Bao +19 more
similarity 0.62
Abstract

Discovering broadly neutralizing antibodies (bnAbs) from human natural immune repertoires remains a fundamental challenge in immunology, hindered by: the extreme rarity of bnAb, incomplete understanding of their cellular origins across pathogens, and the inability of existing computational tools to generalize across emerging viral threats. Here we present ImmuneAgent, a closed-loop AI system that integrates multimodal reasoning with continual meta-learning and wet-lab feedback to overcome these barriers. Applied to screen the natural BCR repertoires from vaccinated or infected cohorts, the system achieves a ~55% neutralization antibody discovery rate (60 of 110 cloned candidates) and a ~11% bnAb yield (12 of 110), substantially outperforming a state-of-the-art sequence-based neutralization predictor or cofolding models evaluated at the same cloning budget. Five ImmuneAgent-discovered antibodies conferred 100% in vivo protection against lethal influenza challenge, comparable to the clinical-stage therapeutic MEDI8852. The system recovered the cellular and structural determinants of bnAb activity and identified FCRL5+CD27+ atypical memory B cells as a conserved bnAb reservoir and hydrophobic interface enrichment as a cross-viral structural signature, which generalized to unseen antigens, discovering human metapneumovirus (hMPV) cross-neutralizing and human papillomavirus (HPV)-neutralizing antibodies without antigen-specific sorting. These results validate that ImmuneAgent is a generalizable framework for rapid therapeutic antibody discovery against emerging viral threats.

0.20

PulmoWorld: An Asynchronous Multimodal Medical World Model for Longitudinal Pneumonia Dynamics

cs.CV ·2026-10-28 ·Cheng Tang, Xinyu Zhang, Jiawei Chen, Minghui Zhang, Shaocong Wei +12 more
similarity 0.61
Abstract · 49 pages, 17 figures

Pneumonia changes across respiration, inflammation, and organ function, while the measurements that describe it arrive at different times and are often incomplete. We introduce PULMOWORLD, a world model for longitudinal pneumonia dynamics that connects asynchronous state estimation, recursive simulation, and evidence-constrained planning. History-aware filtering separates state propagation from observation-driven correction, so a measurement updates the shared belief only when it is observed. That belief supports recursive forecasts of clinical values and modality representations, and summaries of future prognosis. Cap-MBRL searches imagined continuations inside an authorized action set and replaces a frozen fallback only when a candidate meets the risk budget and a predicted-cost margin. On the pneumonia cohort MASS, recursive forecasts are competitive with task-trained sequence models, and simulated future states retain prognostic information. Trained separately on public MIMIC-IV-CXR chest radiographs and clinical trajectories, this model improves prognostic discrimination over latest-value fusion in development and is competitive on long-horizon error on the locked pneumonia panel. In five known-mechanism MASS-Syn environments, Cap-MBRL lowers selection regret relative to direct fallback execution.

0.17

CaMeWM: A Causal Medical World Model for Generative Tumor Evolution and Treatment Planning

cs.CV cs.LG ·2026-10-17 ·Huanlong Gao, Xuelei He, Fengjun Zhao, Xiaowei He
similarity 0.61
Abstract · 30 pages,8 figures,12 tables,including supplementary material

Treatment planning is intrinsically counterfactual: clinicians must compare how a patient's tumor and survival would evolve under competing regimens, whereas a retrospective cohort records only the regimen received and one follow-up scan. A treatment-conditioned generator trained on such data can therefore reproduce historical treatment allocation rather than simulate the interventional disease dynamics needed to rank regimens. We introduce \textbf{CaMeWM}, a causal medical world model for supported post-TACE tumor evolution and treatment planning. CaMeWM implements one intervention-to-decision loop rather than three independent prediction tasks: it first admits a queried regimen only for clinically comparable histories with empirical treatment support; it then generates a distribution of lesion-local follow-up worlds through an action-conditioned response descriptor, deterministic anchor, and residual 3D diffusion transition; and it finally maps sampled worlds to restricted mean survival time (RMST) with a response-Cox utility model. Under pre-treatment adjustment and positivity, this loop estimates a prespecified, support-restricted g-formula target; all selection and nuisance estimation are fold-local, and the induced policy is evaluated by cross-fitted, censoring-adjusted doubly robust estimation. Across 79 paired out-of-fold episodes, CaMeWM achieves 0.618 SSIM and 0.528 change-map SSIM for follow-up CT transition, while its generated-world survival pathway attains a 0.615 C-index; factual-only AIPW estimates a 9.60-week RMST gain (95\% CI 0.61--18.13) for the frozen policy. CaMeWM provides an inspectable basis for retrospective, support-restricted treatment planning.

0.33

Causal multi-modal AI for personalized chemosensitivity prediction

cs.AI ·2026-09-11 ·Dhruva Biswas, Jeroen Berrevoets, Alec McClean, Linus Bao, Jungkyu Park +29 more
highly cited similarity 0.60
Abstract

Chemotherapy improves survival for some patients with breast cancer, but doctors cannot reliably predict who. Current guidelines rely on recurrence scores as a proxy for treatment benefit, which may contribute to the overprescription of chemotherapy. Here we present a causal multi-modal AI model that predicts personalized chemosensitivity using routinely collected pathology and clinical information. We developed our model on a multi-national dataset of 9,141 patients (twelve cohorts, nine countries) and evaluated it on another 1,994 patients (five cohorts, three countries). The model generated treatment-specific recurrence probabilities for each patient, with near-perfect calibration and strong prognostic discrimination across both 5- and 10-year follow-up horizons. Moreover, its chemotherapy benefit predictions demonstrated robust predictive performance, and out-performed existing recurrence-score-based tests. Compared to the standard of care, using the model to support personally tailored therapeutic decisions could reduce the number of patients receiving chemotherapy by 30% while achieving the same recurrence-free rate. Tumors predicted to be highly chemosensitive displayed concordant molecular and morphological programs of proliferation, cell cycle progression, and replication stress. The model's predictive capabilities transferred zero-shot to non-breast cancers, indicating our causal multi-modal AI approach may provide a universal strategy to predict treatment outcomes across cancer types.

0.52

scDEFT: A deep learning framework for drug-effect prediction and counterfactual reasoning

cs.LG q-bio.QM ·2026-09-09 ·Murthy Devarakonda
similarity 0.60
Abstract · 21 Pages, 5 Figures, 3 Tables, and a Supplementary Notes section for overflow material. Approximately 3000 words (excluding Figures, Tables,…

Longitudinal single cell atlases now capture matched pre treatment and post treatment states from responders and non responders, presenting an opportunity to mechanistically explain why two patients on the same drug diverge. We introduce scDEFT (single cell Drug EFfect Transducer), which treats a drug as a conditioning operator on cell representations, enabling prediction and explanation. In scDEFT, feature wise linear modulation produces drug conditioned cell latents, learned under abundant per cell supervision and then frozen. Two independent heads aggregate those latents over shared transcriptional neighborhoods to predict drug induced state change and responder status. A backward stage ranks the latent dimensions by how strongly they separate responders from non responders and maps them to genes under a cell composition control. On a harmonized inflammatory bowel disease atlas of 1.16 million cells, three cohorts and two drug classes, scDEFT predicts state change at 45% of the baseline to reproducibility ceiling headroom and stratifies responders before treatment at AUROC 0.70, where standard predictors remain at chance. These predictions and the drivers behind them support target and co target nomination, patient stratification, and counterfactual prediction of unseen drug cohort effects.

0.12

JEPA-Anything: Learning Predictive Models across Different Worlds

cs.CL ·2026-09-17 ·Taoyong Cui, Zhongyao Wang, Xinyue Xu, Weiyang Liu, Zhaochen Yu +8 more
code/datahighly cited similarity 0.59
Abstract · Code: https://github.com/Gen-Verse/JEPA-Anything

World modeling enables intelligence to anticipate consequences, guide interventions, and learn from interaction. Yet predictive models remain domain-specific: can a common learning principle support world modeling across radically different systems? We introduce JEPA-Anything, a domain-agnostic framework based on orthogonal predictive factorization (OPF). Extending joint-embedding predictive architectures, OPF decomposes latent targets into complementary factors, learns them through dedicated pathways, and recombines them within a shared predictive design. We evaluate JEPA-Anything across seven domains: vision, biology, clinical trajectories, control, molecular dynamics, physical fields, and weather. Experiments span representation learning, intervention prediction, out-of-distribution generalization, and long-horizon dynamics, including 10 matched dynamics tasks, forecasting of over 1,000 clinical events, and 100-step molecular rollouts across four systems. Against matched JEPA baselines, JEPA-Anything improves reported metrics on all 10 dynamics tasks and reduces single-intervention prediction error on Interventional Pong by 34.8%. It achieves the lowest one-step and 100-step molecular errors among compared methods in all four systems. Beyond prediction, a factor-nominated biological intervention receives experimental support in cell co-cultures, patient-derived organoids, tumor fragments, and mice; latent orbital modes recover the Keplerian scaling exponent with a fitted slope of -1.4991. These results support a common factorized predictive principle across heterogeneous worlds, connecting world modeling with intervention and experimentally grounded scientific discovery. Code: https://github.com/Gen-Verse/JEPA-Anything

0.50

CellCanon: An Agentic Cellular World Model for Prediction, Explanation, and Observation-Driven Updating

cs.AI q-bio.QM ·2026-11-04 ·Zhaokang Liang, Shuyang Zhuang, Xiaoran Jiao, Hao Chen
benchmarkcode/datahot direction similarity 0.59
Abstract · 31 pages, 5 figures. Code: https://github.com/ZhaokangLiang123/CellCanon

Biological discovery requires using molecular knowledge and new measurements to infer responses beyond the conditions already observed. We introduce CellCanon, the first agentic cellular world model to unify single-cell expression prediction, evidence-grounded explanation, and observation-driven updating. Its predictive core reuses condition-level biological evidence across gene-specific numerical readouts to guide single-cell expression generation. A shared world state links predictions, acquired measurements, and source-linked claims, supporting explanation and revision. On 339 held-out SciPlex3 conditions across three cell lines, CellCanon improves differential-expression AUPRC and Macro-F1 over the best baseline for each metric by 63.3% and 17.3%, respectively, and direction Macro-F1 by 7.2%. Relative to gene-wise reasoning on matched drug-cell cohorts, measured language-model token use falls by 99.77% for Predict and 98.41% for Explain. On the source-grounded benchmark, Explain correctly answers all answerable questions with supporting proofs and identifies all insufficient-evidence cases. In simulated experimental feedback, Update uses one measured source context per drug to exceed the best fine-tuned baselines in differential-expression AUPRC and Macro-F1 without changing model weights. Together, these capabilities support a cumulative account of cellular responses, with predictions and biological judgments that can be revised as evidence accumulates.

0.36

Conserved Immune Topology Improves Pathology Foundation Model Generalization for Cross-Cancer MSI-H Prediction

cs.CV ·2026-09-04 ·Dasari Naga Raju
published similarity 0.59
Abstract · Accepted at the ECCV 2026 Workshop on Medical Foundation Models and Benchmarks (MedFM-Bench). 15 pages, 2 figures

Pathology foundation models integrated with multiple instance learning achieve competitive accuracy within single-cancer cohorts, yet cross-cancer generalization remains unresolved due to organ-specific histological and architectural differences. In this paper, we propose Conserved Immune Topology (CIT), a lightweight spatial representation for cross-cancer MSI-H prediction that augments foundation-model embeddings with biologically motivated immune descriptors. CIT uses unsupervised clustering to identify immune-associated tiles, then encodes tertiary lymphoid structures, peritumoral immune reactions, multi-scale tumor-infiltrating lymphocyte density, and immune-tumor mixing from frozen foundation-model embeddings and tile coordinates without requiring annotations or target-domain data. The proposed method was evaluated under cross-site and cross-cancer settings using CPTAC-COAD and TCGA-STAD cohorts, which introduce scanner variability, distribution shifts, and organ-specific architectural variations. Zero-shot cross-cancer transfer with CIT increased TransMIL AUC from 0.6627 to 0.7161, an absolute gain of 0.0534 (p=0.003), with consistent improvements across all three MIL aggregators. These results suggest that spatial immune topology provides potentially an organ-invariant representation for MSI-H prediction, supporting cross-cancer generalization of pathology foundation models.

0.34